With the increasing understanding of the role of the MDM2-MDMX heterodimer as an active E3 ligase complex in mediating p53-dependent and independent oncogenic activities, targeting the MDM2-MDMX heterodimer presents a unique therapeutic opportunity for anti-cancer drug development. Here, MDM2 is linked to cancer.